Organicell Regenerative Medicine, Inc. (OCEL) Comparison with companies in other sectors?

Organicell Regenerative Medicine, Inc. has a share price of 7.28M. You can analyze Organicell Regenerative Medicine, Inc. (OCEL) competitors across different market sectors through stock heatmaps.

What are OCEL's NET and operating margins?

Organicell Regenerative Medicine, Inc. (OCEL) operating margin is around -1.02, and net profit margin is approximately -0.67 as of the latest reports.

In what way does OCEL's earnings per share (EPS) trend reflect its financial momentum?

Organicell Regenerative Medicine, Inc. (OCEL) EPS is -1.75 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Organicell Regenerative Medicine, Inc. is -1.57, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Organicell Regenerative Medicine, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Organicell Regenerative Medicine, Inc. like P/E which is -5.84, P/B which is -8.29, and PEG which is -0.06. Compare them with sector averages to evaluate if the stock is priced fairly.

Organicell Regenerative Medicine, Inc.

OCEL•PNK

Healthcare

Biotechnology

$2.74

$-0.01(-0.27%)

Organicell Regenerative Medicine, Inc. (OCEL) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-1.75

P/E Ratio

-1.57

ROE

1.71%

Net Margin

-0.67%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$19.97M

Shares OutstandingTotal number of shares issued

$7.28M

Book Value/ShareNet worth per share

$-0.33

Revenue/ShareAnnual revenue per share

$0.70

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-1.75

Net MarginNet income as percentage of revenue

-66.83%

Operating MarginOperating income as percentage of revenue

-101.82%

ROEReturn on shareholders' equity

170.89%

ROAReturn on total assets

-207.80%

ROCEReturn on capital employed

225.14%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.23

Cash/ShareCash and equivalents per share

$0.09

FCF YieldFree cash flow as percentage of market cap

-7.19%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for OCELFinancial Ratios Analysis details for OCEL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for OCELSector Benchmarking details for OCEL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Organicell Regenerative Medicine, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Organicell Regenerative Medicine, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Organicell Regenerative Medicine, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Organicell Regenerative Medicine, Inc.

For Organicell Regenerative Medicine, Inc., essential financial indicators include EPS -1.75, PE -1.57, and ROE 1.71. These key ratios reveal insights into Organicell Regenerative Medicine, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Organicell Regenerative Medicine, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Organicell Regenerative Medicine, Inc.

Metrics like Net Margin -66.83% and ROA -207.80% shed light on how well Organicell Regenerative Medicine, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Organicell Regenerative Medicine, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Organicell Regenerative Medicine, Inc.

Using ratios such as P/B Ratio -8.29 and PEG Ratio -0.06, investors can assess whether Organicell Regenerative Medicine, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Organicell Regenerative Medicine, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Organicell Regenerative Medicine, Inc.

Financial health indicators, such as Debt/Equity Ratio -0.05 and Cash Flow $-0.23, provide a snapshot of Organicell Regenerative Medicine, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Organicell Regenerative Medicine, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Organicell Regenerative Medicine, Inc.

Investing in Organicell Regenerative Medicine, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Organicell Regenerative Medicine, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;